Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028048
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028048
Oncology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 270 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of oncology drugs Market
The global oncology drugs market has witnessed substantial growth due to the rising burden of cancer and continuous advancements in treatment technologies. The market was valued at USD 256.46 billion in 2025 and is projected to reach USD 286.36 billion in 2026, further expanding to USD 697.59 billion by 2034, registering a robust CAGR of 11.77% during 2026-2034.
North America dominated the global market in 2025, accounting for 45.44% of the total share, driven by high healthcare spending, rapid adoption of innovative therapies, and strong regulatory support.
Oncology drugs are prescription medications used to treat various cancers, including solid tumors and hematological malignancies. Increasing adoption of early-stage cancer treatment, supported by advancements in biomarker testing and diagnostics, is significantly driving market growth.
Market Trends
One of the key trends shaping the oncology drugs market is the early use of high-value targeted therapies. The industry is shifting from treating advanced-stage cancers to addressing early-stage conditions, improving survival rates and reducing recurrence risks.
Additionally, the development of subcutaneous drug formulations is gaining traction. These formulations improve patient convenience, reduce hospital time, and enhance treatment efficiency, leading to faster adoption even in competitive drug categories.
Another important trend is the increasing reliance on companion diagnostics, which helps tailor treatments to specific patient profiles, improving clinical outcomes.
Market Drivers
Rising Cancer Burden and Advanced Drug Launches
The increasing prevalence of cancer worldwide is a major growth driver. Factors such as smoking, pollution, lifestyle changes, and aging populations contribute to the rising number of cancer cases.
Simultaneously, the launch of advanced therapies such as antibody-drug conjugates and targeted drugs has significantly improved treatment effectiveness. These therapies combine precision targeting with strong tumor-killing capabilities, enhancing patient outcomes.
Growing Adoption of Combination Therapies
Combination therapies, including immunotherapy with targeted drugs, are creating new growth opportunities. These treatments improve response rates and expand the eligible patient population, driving market expansion.
Market Restraints
Despite strong growth, the market faces challenges due to high treatment costs and reimbursement pressures. Many advanced oncology drugs require strong clinical evidence to justify their cost, leading to delays in reimbursement approvals.
Additionally, limited access to specialized treatment centers and strict regulatory requirements can restrict the adoption of innovative therapies, especially in developing regions.
Market Challenges
A significant challenge in the oncology drugs market is the complex manufacturing process of advanced therapies such as radiopharmaceuticals and antibody-drug conjugates. These treatments require specialized infrastructure, strict handling conditions, and precise logistics.
Supply chain constraints and short shelf-life of certain drugs also hinder widespread accessibility, impacting overall market growth.
Segmentation Analysis
By Drug Class
Targeted drugs dominate the market due to their high efficacy and precision in treating cancer. These include monoclonal antibodies and other advanced therapies. Cytotoxic drugs also continue to grow steadily due to their widespread use.
By Therapy
Targeted therapy leads the segment owing to its ability to specifically attack cancer cells while minimizing damage to healthy tissues. Immunotherapy is expected to grow rapidly due to its effectiveness in enhancing the body's immune response.
By Indication
Lung cancer holds the largest market share due to its high prevalence globally. Breast cancer is also expected to witness significant growth due to increasing awareness and early diagnosis.
By Dosage Form
Injectable drugs dominate the market, as most oncology treatments are administered in clinical settings for better efficacy and monitoring.
By Distribution Channel
Hospital pharmacies lead the market, accounting for the largest share due to the need for specialized administration and monitoring of oncology drugs.
Regional Insights
- North America: Largest market with USD 108.79 billion in 2025, growing to USD 118.41 billion in 2026, driven by innovation and strong healthcare infrastructure.
- Europe: Valued at USD 56.86 billion in 2025 and USD 63.69 billion in 2026, supported by reimbursement policies and advanced treatment adoption.
- Asia Pacific: Rapidly growing region with USD 50.95 billion in 2025 and USD 57.82 billion in 2026, driven by rising patient population in China and India.
- Latin America & Middle East & Africa: Emerging markets with steady growth due to increasing healthcare investment and patient awareness.
Competitive Landscape
The oncology drugs market is moderately fragmented, with major players focusing on innovation, acquisitions, and expanding product pipelines. Leading companies include Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, and Roche. These firms dominate due to their strong portfolios of blockbuster cancer drugs and continuous R&D investments.
Conclusion
The global oncology drugs market is poised for significant expansion, growing from USD 256.46 billion in 2025 to USD 697.59 billion by 2034. This growth is primarily driven by rising cancer prevalence, increasing adoption of targeted and combination therapies, and continuous innovation in drug development.
However, challenges such as high treatment costs, reimbursement barriers, and complex manufacturing processes remain critical concerns. Despite these hurdles, advancements in personalized medicine, early diagnosis, and novel therapeutic approaches are expected to reshape the market landscape.
Segmentation By Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region
By Drug Class * Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
- Targeted Drugs
- Monoclonal Antibodies
- Others
- Hormonal Drugs
- Others
By Therapy * Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
By Indication * Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Others
By Dosage Form * Solid
- Tablets
- Capsules
- Liquid
- Injectable
- Prefilled Syringes
- Others
By Distribution Channel * Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region * North America (By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- U.S. (By Drug Class)
- Canada (By Drug Class)
- Europe (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- U.K. (By Drug Class)
- Germany (By Drug Class)
- France (By Drug Class)
- Italy (By Drug Class)
- Spain (By Drug Class)
- Scandinavia (By Drug Class)
- Rest of Europe (By Drug Class)
- Asia Pacific (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- Japan (By Drug Class)
- China (By Drug Class)
- India (By Drug Class)
- Australia (By Drug Class)
- Southeast Asia (By Drug Class)
- Rest of Asia Pacific (By Drug Class)
- Latin America (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- Brazil (By Drug Class)
- Mexico (By Drug Class)
- Rest of Latin America (By Drug Class)
- Middle East & Africa (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- South Africa (By Drug Class)
- GCC (By Drug Class)
- Rest of the Middle East & Africa (By Drug Class)
Product Code: FBI103431
Table of Content
1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Cancer, By Region/Country, 2025
- 4.2. Overview of Different Oncology Drugs With Respect to Regulatory Approvals and Clinical Trials
- 4.3. Pricing Analysis, Key Brands / Key Players, 2025
- 4.4. Key Industry Development (Mergers, Acquisitions and Partnerships)
5. Global Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Cytotoxic Drugs
- 5.1.1.1. Alkylating Agents
- 5.1.1.2. Antimetabolites
- 5.1.1.3. Others
- 5.1.2. Targeted Drugs
- 5.1.2.1. Monoclonal Antibodies
- 5.1.2.2. Others
- 5.1.3. Hormonal Drugs
- 5.1.4. Others
- 5.1.1. Cytotoxic Drugs
- 5.2. Market Analysis, Insights and Forecast - By Therapy
- 5.2.1. Chemotherapy
- 5.2.2. Targeted Therapy
- 5.2.3. Immunotherapy
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Indication
- 5.3.1. Lung Cancer
- 5.3.2. Stomach Cancer
- 5.3.3. Colorectal Cancer
- 5.3.4. Breast Cancer
- 5.3.5. Prostate Cancer
- 5.3.6. Others
- 5.4. Market Analysis, Insights and Forecast - By Dosage Form
- 5.4.1. Solid
- 5.4.1.1. Tablets
- 5.4.1.2. Capsules
- 5.4.2. Liquid
- 5.4.3. Injectable
- 5.4.3.1. Prefilled Syringes
- 5.4.3.2. Others
- 5.4.1. Solid
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies
- 5.5.3. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast - By Geography
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Cytotoxic Drugs
- 6.1.1.1. Alkylating Agents
- 6.1.1.2. Antimetabolites
- 6.1.1.3. Others
- 6.1.2. Targeted Drugs
- 6.1.2.1. Monoclonal Antibodies
- 6.1.2.2. Others
- 6.1.3. Hormonal Drugs
- 6.1.4. Others
- 6.1.1. Cytotoxic Drugs
- 6.2. Market Analysis, Insights and Forecast - By Therapy
- 6.2.1. Chemotherapy
- 6.2.2. Targeted Therapy
- 6.2.3. Immunotherapy
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Indication
- 6.3.1. Lung Cancer
- 6.3.2. Stomach Cancer
- 6.3.3. Colorectal Cancer
- 6.3.4. Breast Cancer
- 6.3.5. Prostate Cancer
- 6.3.6. Others
- 6.4. Market Analysis, Insights and Forecast - By Dosage Form
- 6.4.1. Solid
- 6.4.1.1. Tablets
- 6.4.1.2. Capsules
- 6.4.2. Liquid
- 6.4.3. Injectable
- 6.4.3.1. Prefilled Syringes
- 6.4.3.2. Others
- 6.4.1. Solid
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies
- 6.5.3. Online Pharmacies
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.1.1. By Drug Class
- 6.6.2. Canada
- 6.6.2.1. By Drug Class
- 6.6.1. U.S.
7. Europe Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Cytotoxic Drugs
- 7.1.1.1. Alkylating Agents
- 7.1.1.2. Antimetabolites
- 7.1.1.3. Others
- 7.1.2. Targeted Drugs
- 7.1.2.1. Monoclonal Antibodies
- 7.1.2.2. Others
- 7.1.3. Hormonal Drugs
- 7.1.4. Others
- 7.1.1. Cytotoxic Drugs
- 7.2. Market Analysis, Insights and Forecast - By Therapy
- 7.2.1. Chemotherapy
- 7.2.2. Targeted Therapy
- 7.2.3. Immunotherapy
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Indication
- 7.3.1. Lung Cancer
- 7.3.2. Stomach Cancer
- 7.3.3. Colorectal Cancer
- 7.3.4. Breast Cancer
- 7.3.5. Prostate Cancer
- 7.3.6. Others
- 7.4. Market Analysis, Insights and Forecast - By Dosage Form
- 7.4.1. Solid
- 7.4.1.1. Tablets
- 7.4.1.2. Capsules
- 7.4.2. Liquid
- 7.4.3. Injectable
- 7.4.3.1. Prefilled Syringes
- 7.4.3.2. Others
- 7.4.1. Solid
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.6.1. U.K
- 7.6.1.1. By Drug Class
- 7.6.2. Germany
- 7.6.2.1. By Drug Class
- 7.6.3. France
- 7.6.3.1. By Drug Class
- 7.6.4. Spain
- 7.6.4.1. By Drug Class
- 7.6.5. Italy
- 7.6.5.1. By Drug Class
- 7.6.6. Scandinavia
- 7.6.6.1. By Drug Class
- 7.6.7. Rest of Europe
- 7.6.7.1. By Drug Class
- 7.6.1. U.K
8. Asia Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Cytotoxic Drugs
- 8.1.1.1. Alkylating Agents
- 8.1.1.2. Antimetabolites
- 8.1.1.3. Others
- 8.1.2. Targeted Drugs
- 8.1.2.1. Monoclonal Antibodies
- 8.1.2.2. Others
- 8.1.3. Hormonal Drugs
- 8.1.4. Others
- 8.1.1. Cytotoxic Drugs
- 8.2. Market Analysis, Insights and Forecast - By Therapy
- 8.2.1. Chemotherapy
- 8.2.2. Targeted Therapy
- 8.2.3. Immunotherapy
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Indication
- 8.3.1. Lung Cancer
- 8.3.2. Stomach Cancer
- 8.3.3. Colorectal Cancer
- 8.3.4. Breast Cancer
- 8.3.5. Prostate Cancer
- 8.3.6. Others
- 8.4. Market Analysis, Insights and Forecast - By Dosage Form
- 8.4.1. Solid
- 8.4.1.1. Tablets
- 8.4.1.2. Capsules
- 8.4.2. Liquid
- 8.4.3. Injectable
- 8.4.3.1. Prefilled Syringes
- 8.4.3.2. Others
- 8.4.1. Solid
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.6.1. Japan
- 8.6.1.1. By Drug Class
- 8.6.2. China
- 8.6.2.1. By Drug Class
- 8.6.3. India
- 8.6.3.1. By Drug Class
- 8.6.4. Australia
- 8.6.4.1. By Drug Class
- 8.6.5. Southeast Asia
- 8.6.5.1. By Drug Class
- 8.6.6. Rest of Asia Pacific
- 8.6.6.1. By Drug Class
- 8.6.1. Japan
9. Latin America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Cytotoxic Drugs
- 9.1.1.1. Alkylating Agents
- 9.1.1.2. Antimetabolites
- 9.1.1.3. Others
- 9.1.2. Targeted Drugs
- 9.1.2.1. Monoclonal Antibodies
- 9.1.2.2. Others
- 9.1.3. Hormonal Drugs
- 9.1.4. Others
- 9.1.1. Cytotoxic Drugs
- 9.2. Market Analysis, Insights and Forecast - By Therapy
- 9.2.1. Chemotherapy
- 9.2.2. Targeted Therapy
- 9.2.3. Immunotherapy
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Indication
- 9.3.1. Lung Cancer
- 9.3.2. Stomach Cancer
- 9.3.3. Colorectal Cancer
- 9.3.4. Breast Cancer
- 9.3.5. Prostate Cancer
- 9.3.6. Others
- 9.4. Market Analysis, Insights and Forecast - By Dosage Form
- 9.4.1. Solid
- 9.4.1.1. Tablets
- 9.4.1.2. Capsules
- 9.4.2. Liquid
- 9.4.3. Injectable
- 9.4.3.1. Prefilled Syringes
- 9.4.3.2. Others
- 9.4.1. Solid
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.6.1. Brazil
- 9.6.1.1. By Drug Class
- 9.6.2. Mexico
- 9.6.2.1. By Drug Class
- 9.6.3. Rest of Latin America
- 9.6.3.1. By Drug Class
- 9.6.1. Brazil
10. Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Cytotoxic Drugs
- 10.1.1.1. Alkylating Agents
- 10.1.1.2. Antimetabolites
- 10.1.1.3. Others
- 10.1.2. Targeted Drugs
- 10.1.2.1. Monoclonal Antibodies
- 10.1.2.2. Others
- 10.1.3. Hormonal Drugs
- 10.1.4. Others
- 10.1.1. Cytotoxic Drugs
- 10.2. Market Analysis, Insights and Forecast - By Therapy
- 10.2.1. Chemotherapy
- 10.2.2. Targeted Therapy
- 10.2.3. Immunotherapy
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Indication
- 10.3.1. Lung Cancer
- 10.3.2. Stomach Cancer
- 10.3.3. Colorectal Cancer
- 10.3.4. Breast Cancer
- 10.3.5. Prostate Cancer
- 10.3.6. Others
- 10.4. Market Analysis, Insights and Forecast - By Dosage Form
- 10.4.1. Solid
- 10.4.1.1. Tablets
- 10.4.1.2. Capsules
- 10.4.2. Liquid
- 10.4.3. Injectable
- 10.4.3.1. Prefilled Syringes
- 10.4.3.2. Others
- 10.4.1. Solid
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.6.1. GCC
- 10.6.1.1. By Drug Class
- 10.6.2. South Africa
- 10.6.2.1. By Drug Class
- 10.6.3. Rest of the Middle East & Africa
- 10.6.3.1. By Drug Class
- 10.6.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.2. AbbVie, Inc.
- 11.2.3. Novartis AG
- 11.2.4. Pfizer Inc.
- 11.2.5. AstraZeneca
- 11.2.6. GSK plc
- 11.2.7. Eli Lilly and Company
- 11.2.8. Sanofi
- 11.2.9. Bayer AG
- 11.2.10. Merck & Co., Inc.
- 11.2.11. Bristol-Myers Squibb Company
Product Code: FBI103431
List of Tables
- Table 1: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 3: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 4: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 5: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 6: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 7: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 8: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 9: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 10: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 11: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 12: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 13: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 14: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 15: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 16: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 17: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 18: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 19: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: North America Oncology Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 21: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 22: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 23: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 24: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 25: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 26: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 27: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 28: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 29: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 30: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 31: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 32: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 33: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 34: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 35: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 36: Europe Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 37: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 38: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 39: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 40: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 41: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 42: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 43: France Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 44: France Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 45: France Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 46: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 47: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 48: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 49: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 50: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 51: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 52: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 53: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 54: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 55: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 56: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 57: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 58: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 59: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 60: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 61: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 62: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 63: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 64: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 65: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 66: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 67: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 68: China Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 69: China Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 70: China Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 71: India Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 72: India Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 73: India Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 74: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 75: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 76: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 77: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 78: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 79: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 80: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 81: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 82: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 83: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 84: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 85: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 86: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 87: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 88: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 89: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 90: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 91: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 92: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 93: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 94: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 95: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 96: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 97: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 98: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 99: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 100: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 101: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 102: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 103: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 104: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 105: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 106: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 107: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 108: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 109: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 110: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
- Table 111: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
- Table 112: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
- Table 113: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 114: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 115: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 116: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 117: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 118: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 119: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 120: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
- Table 121: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 122: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
- Table 123: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
List of Figures
- Figure 1: Global Oncology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Oncology Drugs Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Oncology Drugs Market Value Share (%), by Therapy, 2025 & 2034
- Figure 4: Global Oncology Drugs Market Value Share (%), by Indication, 2025 & 2034
- Figure 5: Global Oncology Drugs Market Value Share (%), by Dosage Form, 2025 & 2034
- Figure 6: Global Oncology Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 7: Global Oncology Drugs Market Value (USD billion), by Region, 2025 & 2034
- Figure 8: North America Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 9: North America Oncology Drugs Market Value Share (%), by Drug Class, 2025
- Figure 10: North America Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 11: North America Oncology Drugs Market Value Share (%), by Therapy, 2025
- Figure 12: North America Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 13: North America Oncology Drugs Market Value Share (%), by Indication, 2025
- Figure 14: North America Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
- Figure 15: North America Oncology Drugs Market Value Share (%), by Dosage Form, 2025
- Figure 16: North America Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 17: North America Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 18: North America Oncology Drugs Market Value (USD billion), By Country, 2025 & 2034
- Figure 19: North America Oncology Drugs Market Value Share (%), By Country, 2025
- Figure 20: Europe Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 21: Europe Oncology Drugs Market Value Share (%), by Drug Class, 2025
- Figure 22: Europe Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 23: Europe Oncology Drugs Market Value Share (%), by Therapy, 2025
- Figure 24: Europe Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 25: Europe Oncology Drugs Market Value Share (%), by Indication, 2025
- Figure 26: Europe Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
- Figure 27: Europe Oncology Drugs Market Value Share (%), by Dosage Form, 2025
- Figure 28: Europe Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 29: Europe Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 33: Asia Pacific Oncology Drugs Market Value Share (%), by Drug Class, 2025
- Figure 34: Asia Pacific Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 35: Asia Pacific Oncology Drugs Market Value Share (%), by Therapy, 2025
- Figure 36: Asia Pacific Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 37: Asia Pacific Oncology Drugs Market Value Share (%), by Indication, 2025
- Figure 38: Asia Pacific Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
- Figure 39: Asia Pacific Oncology Drugs Market Value Share (%), by Dosage Form, 2025
- Figure 40: Asia Pacific Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 41: Asia Pacific Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 42: Asia Pacific Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 45: Latin America Oncology Drugs Market Value Share (%), by Drug Class, 2025
- Figure 46: Latin America Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 47: Latin America Oncology Drugs Market Value Share (%), by Therapy, 2025
- Figure 48: Latin America Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 49: Latin America Oncology Drugs Market Value Share (%), by Indication, 2025
- Figure 50: Latin America Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
- Figure 51: Latin America Oncology Drugs Market Value Share (%), by Dosage Form, 2025
- Figure 52: Latin America Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 53: Latin America Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Latin America Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 57: Middle East & Africa Oncology Drugs Market Value Share (%), by Drug Class, 2025
- Figure 58: Middle East & Africa Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 59: Middle East & Africa Oncology Drugs Market Value Share (%), by Therapy, 2025
- Figure 60: Middle East & Africa Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
- Figure 61: Middle East & Africa Oncology Drugs Market Value Share (%), by Indication, 2025
- Figure 62: Middle East & Africa Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
- Figure 63: Middle East & Africa Oncology Drugs Market Value Share (%), by Dosage Form, 2025
- Figure 64: Middle East & Africa Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 65: Middle East & Africa Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Oncology Drugs Market Share (%), By Company, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.